4
SPECIFIC AV ACCESS RELATED PRECAUTIONS
t 5IFTBGFUZBOEFGGFDUJWFOFTTPGUIFEFWJDFXIFOVTFEJODFOUSBMWFJOTIBTOPUCFFOFWBMVBUFE
t 5IFTBGFUZBOEFGGFDUJWFOFTTPGUIFEFWJDFXIFOQMBDFEBDSPTTUIFBOUFDVCJUBMGPTTBIBTOPUCFFOFWBMVBUFE
t 5IFFGGFDUTPGEJSFDUDBOOVMBUJPOPGUIFDPWFSFETUFOUIBWFOPUCFFOFWBMVBUFE/PUJGZUIFQBUJFOUUIBUUIFDPWFSFETUFOUTIPVME
not be directly cannulated for hemodialysis and that applying pressure to the implant area should be avoided.
POTENTIAL COMPLICATIONS AND ADVERSE EVENTS
Complications and Adverse Events associated with the use of the
C
OVERA
™ P
LUS
Vascular Covered Stent may include the usual
complications associated with endovascular stent and covered stent placement and dialysis shunt revisions.
Potential complications may include, but are not limited to:
Abscess; access site infection; allergic/anaphylactoid reaction; amputation; aneurysm; angina/coronary ischemia; arteriovenous
fistula; arrhythmia; bleeding at access site; bypass surgery; cerebrovascular accident; congestive heart failure; embolization;
extravasation; fever; hematoma; hemorrhage; hemoptysis; hypotension/hypertension; intimal injury/dissection; ischemia/
infarction of tissue/organ; infection; myocardial infarction; occlusion; pain; pulmonary embolism; perforation; prolonged
bleeding; pseudoaneurysm; rash; reaction to contrast; renal failure; renal toxicity; radiation injury; restenosis; septicemia/
bacteremia; sepsis; stroke; thrombus; vasospasm; ventricular fibrillation; vessel rupture and death.
AV Access specific adverse events may include, but are not limited to:
Arm or hand edema; steal syndrome; and face or neck edema.
Covered stent specific events that could be associated with clinical complications include, but are not limited to:
Embolism; fracture; insufficient covered stent expansion; kinking; malapposition; migration and misplacement; and side branch
occlusion.
Delivery System specific events that could be associated with clinical complications include, but are not limited to:
Blood leakage from delivery system; bond joint failures; delivery system kinking; detachment of parts; failure to deploy; high
deployment forces; inability to track to target location; inaccurate deployment; incompatibility with accessory devices; no
visibility under fluoroscopy; and premature deployment.
COVERED STENT SIZE SELECTION
Special care must be taken to ensure that an appropriately sized device is selected. In the case of a diameter difference between
the inflow and the outflow end, always use the inflow vessel or AV graft diameter as the reference vessel diameter.
Table 1: Covered Stent Diameter Selection
Covered Stent Diameter
Recommended Oversizing
Reference Vessel Diameter
6 mm
0.5 mm – 1.5 mm
4.5 mm – 5.5 mm
7 mm
0.5 mm – 1.5 mm
5.5 mm – 6.5 mm
8 mm
1 mm – 2 mm
6 mm – 7 mm
9 mm
1 mm – 2 mm
7 mm – 8 mm
10 mm
1 mm – 2 mm
8 mm – 9 mm
Covered Stent Length
Ensure the selected covered stent length covers the entire lesion and both ends of the implant extend at least 5 mm into the non-
diseased segment of the vessel. In the case of overlapping devices, at least 10 mm of overlap between devices is recommended.
For covered stent placements in the proximal cephalic arch, select the length so that the ostial lesion is fully covered and so that
the proximal covered stent end does not compromise the flow in the axillary/subclavian vein. Ensure that the covered stent end
extends at least 10 mm beyond the arch curvature into the straight distal cephalic vein segment.
NOTE: The
C
OVERA
™
P
LUS
Vascular Covered Stent foreshortening is ≤ 13%.
Reusing this medical device bears the risk of cross-patient contamination as medical devices – particularly those with long
and small lumina, joints, and/or crevices between components – are difficult or impossible to clean once body fluids or tissues
with potential pyrogenic or microbial contamination have had contact with the medical device for an indeterminable period
of time. The residue of biological material can promote the contamination of the device with pyrogens or microorganisms
which may lead to infectious complications or death.
t
DO NOT
use in patients with uncorrectable coagulation disorders.
t
DO NOT
use in patients that cannot be adequately pre-medicated.
t
DO NOT
use in patients who have a known allergy or sensitivity to contrast media.
t
DO NOT
use in patients with known hypersensitivity to nickel-titanium or tantalum.
t
DO NOT
use the device in patients where full expansion of an appropriately sized PTA balloon catheter could not be achieved
during pre-dilation with an angioplasty balloon.
t
DO NOT
use in patients who cannot receive recommended antiplatelet and/or anticoagulation therapy.
t
DO NOT
use in patients with functionally relevant arterial obstruction of the inflow path, poor outflow or no distal runoff.
t
DO NOT
place in patients with a target lesion with a large amount of adjacent acute or subacute thrombus.
t 1MBDJOHBDPWFSFETUFOUBDSPTTBWFTTFMTJEFCSBODINBZJNQFEFCMPPEGMPXBOEIJOEFSPSQSFWFOUGVUVSFQSPDFEVSFT
t
DO NOT
use for the treatment of lesions that would prevent a surgical salvage bypass procedure.
t
DO NOT
track and deploy the 9F endovascular system across the aorto-iliac bifurcation in crossover fashion since this may
result in failure to deploy the covered stent.
t 5IFMPOHUFSNPVUDPNFTGPMMPXJOHSFQFBUEJMBUBUJPOPGFOEPUIFMJBMJ[FEDPWFSFETUFOUTBSFVOLOPXO
SPECIFIC AV ACCESS RELATED WARNINGS
t 5IFEFWJDFIBTOPUCFFOUFTUFEGPSUSBDLJOHBOEEFQMPZNFOUBSPVOEBO"7MPPQHSBGU
t
DO NOT
use in patients whose AV access grafts have been implanted for less than 30 days or in an immature fistula.
t $PWFSFETUFOUQMBDFNFOUCFZPOEUIFPTUJVNPGUIFDFQIBMJDWFJOJOUPUIFBYJMMBSZTVCDMBWJBOWFJONBZIJOEFSPSQSFWFOUGVUVSF
access.
t
DO NOT
use in patients with bacteremia or septicaemia and/or evidence of fistula or graft infection.
PRECAUTIONS
t 1SJPSUPDPWFSFETUFOUJNQMBOUBUJPOSFGFSUPUIFTJ[JOHUBCMF 5BCMFBOESFBEUIF*OTUSVDUJPOTGPS6TF
t 5IFEFMJWFSZTZTUFNJTOPUJOUFOEFEGPSBOZVTFPUIFSUIBODPWFSFETUFOUEFQMPZNFOU
t %VSJOHEFWJDFQMBDFNFOUTJODSPTTPWFSUFDIOJRVFNBJOUBJOUIFQSPYJNBMDPWFSFETUFOUFOEJOBTUSBJHIUQPTJUJPOUISPVHIPVU
deployment.
t 5IFDPWFSFETUFOU JNQMBOUDBOOPUCFSFQPTJUJPOFEPSSFDBQUVSFEBGUFSUPUBMPSQBSUJBMEFQMPZNFOU
t 0ODFQBSUJBMMZPSGVMMZEFQMPZFEUIFDPWFSFETUFOUDBOOPUCFSFUSBDUFEPSSFNPVOUFEPOUPUIFEFMJWFSZTZTUFN
t *GVOVTVBMSFTJTUBODFJTNFUEVSJOHDPWFSFETUFOUTZTUFNJOUSPEVDUJPOUIFTZTUFNTIPVMECFSFNPWFEBOEBOPUIFSDPWFSFE
stent system should be used.
t
DO NOT
introduce or manipulate the delivery system without an appropriately sized guidewire and without fluoroscopic
guidance.
t
DO NOT
use a kinked delivery system.
t 'PS DPOUSBMBUFSBM QSPDFEVSFT B MPOH DSPTTPWFS JOUSPEVDFS TIFBUI PS HVJEJOH DBUIFUFS NVTU CF QMBDFE BDSPTT UIF BPSUPJMJBD
bifurcation. Make sure that the proximal covered stent end is positioned in a straight section of the vessel during deployment.
t %VSJOHDPWFSFETUFOUSFMFBTF
DO NOT
hold the 30 cm long distal catheter assembly segment as it must be free to move and
slide into the white stability sheath.
t $BSFGVM BUUFOUJPO CZ UIF PQFSBUPS JT XBSSBOUFE UP NJUJHBUF UIF QPUFOUJBM GPS EJTUBM NJHSBUJPO PG UIF DPWFSFE TUFOU EVSJOH
deployment.
t 5IFDPWFSFETUFOUDBOOPUCFQPTUEJMBUFECFZPOEJUTMBCFMMFEEJBNFUFS
t 5IFTBGFUZBOEFGGFDUJWFOFTTPGUIFEFWJDFXIFOQMBDFEBDSPTTBOBOFVSZTNPSBQTFVEPBOFVSZTNIBTOPUCFFOFWBMVBUFE
t 5IFTBGFUZBOEFGGFDUJWFOFTTPGUIFEFWJDFXIFOQMBDFEBDSPTTBQSFWJPVTMZQMBDFECBSFNFUBMTUFOUIBTOPUCFFOFWBMVBUFE
t 5IFTBGFUZBOEFGGFDUJWFOFTTPGUIFEFWJDFXIFOQMBDFEJOUIFQPQMJUFBMBSUFSZIBTOPUCFFOFWBMVBUFE
t 5IFTBGFUZBOEFGGFDUJWFOFTTPGUIFEFWJDFXIFOVTFEJOQFEJBUSJDTIBTOPUCFFOFWBMVBUFE
t 5IF EFWJDF IBT OPU CFFO UFTUFE GPS VTF JO BO PWFSMBQQFE DPOEJUJPO XJUI B CBSF NFUBM TUFOU PS DPWFSFE TUFOUT GSPN PUIFS
manufacturers.
t )JHIFSEFQMPZNFOUGPSDFNBZCFFODPVOUFSFEXJUIMPOHFSMFOHUIDPWFSFETUFOUT
Summary of Contents for COVERA PLUS
Page 41: ...41 10 mm 6 9F 6 9 7 7 9F 0 035 inch 0 89 mm 4 PTA 5 1 6 7 Luer 4 4 8 5 5 5 mm 10 mm...
Page 42: ...42 10 8 8 h 9 9 11 15 mm 10 10 12 13 14 PTA...
Page 67: ......
Page 68: ......
Page 94: ...86 10 8 8 9 9 11 15 mm 10 5 mm 10 mm 10 mm 6 9F 6 9 7 7...
Page 95: ...87 10 12 13 14 PTA 15...
Page 99: ...91 9 7 7 10 8 8 9 5 5 mm 10 mm 10 mm 6 9F 6...
Page 100: ...92 9 11 15 mm 10 10 12 13 14 PTA 15...
Page 104: ...96 NN 6 9F 6 9 7 7 1 9F 2 0 035 inch 0 89 mm 3 4 5 1 6 7 4 4 8 5 5 5 mm 10 mm...
Page 105: ...97 NN 10 10 12 13 14 15 10 8 9 9 11...
Page 119: ...111 9 F 6 9 7 7 8 3 4 PTA 5 1 6 7 4 4 5 5 5 mm 10 mm NN 6...
Page 120: ...112 10 12 13 14 PTA 8 9 9 11 NN F 10...
Page 124: ...116 10 8 8 9 9 11 15 10 10 5 10 6 9F 6 7 9 7...
Page 125: ...117 10 12 13 14 PTA 15...